Search results
Patient dies in Pfizer study of Duchenne gene therapy
BioPharma Dive via Yahoo Finance· 1 day agoPfizer said the patient, a young boy who was treated earlier last year, died suddenly from cardiac...
Pfizer reports patient death in Duchenne gene therapy study
Reuters· 1 day ago, opens new tab experimental gene therapy being tested in a mid-stage trial for a muscle-wasting...
Pfizer reports fatality in Phase II DMD gene therapy study
Clinical Trials Arena via Yahoo Finance· 15 hours agoPfizer has reported the death of a patient in the Phase II DAYLIGHT study of experimental gene...
Pfizer Pauses Gene Therapy Trial for Muscle Disease After Death
Bloomberg· 1 day agoPfizer Inc. paused a study of an experimental gene therapy for muscular dystrophy after a child who...
AstraZeneca pulls its COVID-19 vaccine from the European market
WSB-TV 2 Atlanta· 1 hour agoLONDON — (AP) — The pharma giant AstraZeneca has requested that the European authorization for its...
Pfizer Agrees to Settle More Than 10,000 Zantac Cancer Lawsuits - Bloomberg News
US News & World Report· 11 hours agoUS News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
Pfizer to test third dose of COVID-19 vaccine in children
AOL· 20 hours agoThe decision was made after an analysis showed the two-dose vaccine generated an immune response in...
Pfizer wants the $75 mln left from SAC Capital’s insider trading settlement with SEC
Reuters· 1 day agoPharma company Pfizer told a New York federal judge on Monday that it is entitled to recoup about...
AstraZeneca pulls COVID-19 vaccine from global markets
UPI· 7 hours agoAstraZeneca Wednesday said it was pulling its Vaxzevria COVID-19 vaccine pictured here from sale...
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks via Yahoo Finance· 3 days agoPfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to...